Results 71 to 80 of about 101,541 (346)

PolyMorphine provides extended analgesic-like effects in mice with spared nerve injury. [PDF]

, 2017
Morphine is a well-characterized and effective analgesic commonly used to provide pain relief to patients suffering from both acute and chronic pain conditions.
Chen, Renxun, Kolber, Benedict, Lax, Neil C, Leep, Sarah R, Uhrich, Kathryn, Yu, Lei   +5 more
core   +1 more source

Infant Death due to Cannabis Ingestion

Drug Testing and Analysis, EarlyView.
ABSTRACT A child died in the emergency room of a local hospital a few hours after ingesting a substance the color of cork and the consistency of earth. At home, a modest amount of resinous substance was found. At the hospital, the child exhibited alterations in walking, balance, and consciousness.
Donata Favretto, Antonello Cirnelli, Roberto Pertile, Raffaella Stimamiglio, Clara Cestonaro, Oriana Cuman, Anna Pagliaro, Fabio Mattiazzi, Cristina Basso, Maddalena Galeazzi   +9 more
wiley   +1 more source

Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study

The Lancet Public Health, 2022
Summary: Background: The US overdose crisis is driven by fentanyl, heroin, and prescription opioids. One evidence-based policy response has been to broaden naloxone distribution, but how much naloxone a community would need to reduce the incidence of ...
Michael A Irvine, PhD, Declan Oller, PhD, Jesse Boggis, MPH, Brian Bishop, PharmD, Daniel Coombs, ProfPhD, Eliza Wheeler, MPA, Maya Doe-Simkins, MPH, Alexander Y Walley, ProfMD, Brandon D L Marshall, PhD, Jeffrey Bratberg, PharmD, Traci C Green, ProfPhD   +10 more
doaj  

Identification of the Novel Synthetic Opioid N‐Pyrrolidino Isotonitazene at an Australian Drug Checking Service

Drug Testing and Analysis, EarlyView.
Close collaboration between an Australian drug checking service and an affiliated university laboratory identifies and characterises the novel synthetic opioid N‐pyrrolidino isotonitazene in an expected oxycodone sample presented by a member of the public.
Blake Curtis, Douglas J. Lawes, David Caldicott, Malcolm D. McLeod   +3 more
wiley   +1 more source

Messaging to Increase Public Support for Naloxone Distribution Policies in the United States: Results from a Randomized Survey Experiment. [PDF]

PLoS ONE, 2015
Barriers to public support for naloxone distribution include lack of knowledge, concerns about potential unintended consequences, and lack of sympathy for people at risk of overdose.A randomized survey experiment was conducted with a nationally ...
Marcus A Bachhuber, Emma E McGinty, Alene Kennedy-Hendricks, Jeff Niederdeppe, Colleen L Barry   +4 more
doaj   +1 more source

Efficacy of naloxone in reducing hypoxemia and duration of immobility following focal to bilateral tonic–clonic seizures

Epilepsia Open, EarlyView.
Abstract Objective Evaluating the efficacy of an opioid antagonist, naloxone (NLX), to reduce the severity of post‐ictal hypoxemia and immobility after focal to bilateral tonic–clonic seizures (FBTCS). Methods ENALEPSY is a double‐blind placebo (PCB)‐controlled trial conducted in patients with focal epilepsy undergoing long‐term video‐EEG monitoring ...
Sylvain Rheims, Fatima Chorfa, Véronique Michel, Edouard Hirsch, Louis Maillard, Luc Valton, Fabrice Bartolomei, Philippe Derambure, Vincent Navarro, Julien Biberon, Arielle Crespel, Anca Nica, Martine Lemesle Martin, Laure Mazzola, Jerome Petit, Vincent Rossero, Sébastien Boulogne, Mathilde Leclercq, Laurent Bezin, Catherine Mercier, Pascal Roy, Philippe Ryvlin, on behalf of the ENALEPSY Study Group, V. Michel, M. De Montaudouin, M. Lemesle Martin, P. Kahane, L. Minotti, L. Vercueil, A. S. Jobst, J. Petit, D. Tourniaire, V. Eid, P. Latour, P. Derambure, W. Szurhaj, S. Rheims, H. Catenoix, N. Andre‐Obadia, J. Isnard, A. Montavont, S. Boulogne, F. Bartolomei, A. Trébuchon, A. Mc Gonigal, S. Aubert, S. Lagarde, A. Crespel, P. Gelisse, B. Mercedes, L. Maillard, L. Tyvaert, J. P. Vignal, V. Navarro, S. Dupont, C. Adam, V. Frazzini, V.‐H. Nguyen‐Michel, M. Damiano, V. Lambrecq, A. Biraben, A. Nica, P. Convers, L. Mazzola, E. Hirsch, M. P. Valenti, J. Scholly, C. Behr, L. Valton, M. Denuelle, J. Curot, J. Biberon   +71 more
wiley   +1 more source

Factors associated with gaps in naloxone knowledge: evidence from a 2022 great plains survey

Harm Reduction Journal
Background The rising prevalence of fast-acting opioids in the USA suggests the increased need for non-professional first responder administration of naloxone.
Spencer Cooper-Ohm, Patrick Habecker, Ryan Humeniuk, Rick A. Bevins   +3 more
doaj   +1 more source

Use of urinary naloxone levels in a single provider practice: a case study

Addiction Science & Clinical Practice, 2020
Background Urine drug monitoring for medications for opioid use disorder (MOUD) such as buprenorphine can help to support treatment adherence. The practice of introducing unconsumed medication directly into urine (known as “spiking” samples) has been ...
Jill S. Warrington, Kaitlyn Booth, Gregory S. Warrington, Samuel Francis-Fath   +3 more
doaj   +1 more source

Overdose Prevention and Response A guide for people who use drugs and harm reduction staff in Eastern Europe and Central Asia [PDF]

, 2009
Provides an overview of the drug overdose problem in Eastern Europe and Central Asia; describes overdose symptoms, factors that affect overdose risk, prevention methods, and step-by-step responses to an overdose.
Curtis, Matt, Guterman, Lydia
core  

Heroin Adulterated with the Novel Synthetic Cannabinoid, 5F-MDMB-PINACA: A Case Series [PDF]

, 2020
Introduction: Heroin can be adulterated with various substances that may or may not have pharmacological effects. Here we report a case series of 8 patients who presented to the emergency department after overdose with intravenous heroin preparation ...
Arnold, Ryan, Dela Cruz, Maricel, Ershad, Muhammed, Hamilton, Richard, Khalid, Muhammad M., Mostafa, Ahmed   +5 more
core